Clinical Handbook of Psychotropic Drugs E-Book

• Herausgeber: Hogrefe Publishing
• Kategorie: Fachliteratur
• Sprache: Englisch
• Veröffentlichungsjahr: 2023

Beschreibung

Quick and comprehensive information on psychotropic drugs for adults. Accurate and up-to-date Comparison charts help decision-making Icons with full color Available both in print and online Downloadable patient information sheets More about this book The Clinical Handbook of Psychotropic Drugs has become a standard reference and working tool for psychiatrists, psychologists, physicians, pharmacists, nurses, and other mental health professionals. Independent, unbiased, up-to-date Packed with unique, easy-to-read comparison charts and tables (dosages, side effects, pharmacokinetics, interactions…) for a quick overview of treatment options Succinct, bulleted information on all classes of medication: on- and off-label indications, (US FDA, Health Canada), recommended dosages, US and Canadian trade names, side effects, interactions, pharmacodynamics, precautions in the young, the elderly, and pregnancy, nursing implications, and much more – all you need to know for each class of drug Potential interactions and side effects summarized in comparison charts With instantly recognizable icons and in full color throughout, allowing you to find at a glance all the information you seek Clearly written patient information sheets available for download as printable PDF files This book is a must for everyone who needs an up-to-date, easy-to-use, comprehensive summary of all the most relevant information about psychotropic drugs. New in this edition Antidepressants chapter includes a new section on the NMDA receptor antagonist/CYP2D6 inhibitor combination product (dextromethorphan/bupropion) Antipsychotics updates include revised clozapine monitoring tables which now also contain monitoring requirements for patients with or without non-benign ethnic neutropenia Mood Stabilisers sections on Lithium and Anticonvulsants extensively revised Dementia chapter includes a new section on lecanemab, a new fast-track FDA-approved treatment for Alzheimer's disease Treatment of Substance Use Disorders includes revisions to buprenorphine dosing section that include a rapid micro-induction method (Bernese method) that allows treatment to start without waiting for patient to be in withdrawal Unapproved treatments of Psychiatric Disorders, Natural Health Products, and Pharmacogenetics chapters all substantially revised New formulations and trade names include: Auvelity (dextromethorphan/bupropion extended-release tablets), Invega Hafyera (paliperidone 6-monthly IM injection), Leqembi (lecanemab infusion), Subutex (buprenorphine sublingual tablets), Quviviq (daridorexant tablets)